Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AACR 2020: Liquid Biopsy Company Guardant Health Presents Colorectal Cancer Data, Outlines Plans For Regulatory Approval

Executive Summary

Guardant Health presented new clinical data at this week’s American Association for Cancer Research conference and outlined its growth plans as cancer testing volumes recover after the pandemic.

You may also be interested in...



Investors Pump $257M Into Thrive’s Liquid Biopsy Test

Thrive is developing CancerSEEK, a liquid biopsy test designed to detect cancers at earlier stages of disease.

Guardant Will Collaborate With Janssen On Lung Cancer Companion Diagnostic

The companies expect the Guardant360 CDx liquid-biopsy test to identify patients who will benefit from amivantamab, Janssen’s investigational drug for non-small cell lung cancer.

Grail Raises $390M In Series D Financing To Advance Blood Cancer Test

Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT142336

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel